Evidence map›Paper›PMID 35230472›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022

Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration.

Mirataollah Salabati, Anthony Obeid, Raziyeh Mahmoudzadeh, Omesh Gupta, Allen Chiang, Marc Spirn, Michael A Klufas, Jason Hsu, Wills Switch Study Group

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mirataollah SalabatiMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Anthony ObeidMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Raziyeh MahmoudzadehMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Omesh GuptaMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Allen ChiangMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Marc SpirnMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Michael A KlufasMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA.
Jason HsuMid Atlantic Retina, The Retina Service of Wills Eye Hospital, Suite 1020, 840 Walnut Street, Philadelphia, PA, 19107, USA. jhsu@midatlanticretina.com.ORCID http://orcid.org/0000-0002-2761-4219
Wills Switch Study Group
Wills Eye Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe outcomes of neovascular age-related macular degeneration (nAMD) eyes that were stable on aflibercept but switched to ranibizumab compared to eyes maintained on aflibercept over the same period.

methodsIn this retrospective cohort study, eyes switched from aflibercept to ranibizumab due to intraocular inflammation (IOI) concerns with aflibercept were identified. Data was gathered from 3 visits pre-switch, switch visit (Sw), and 3 visits post-switch (P1, P2, P3). Similar data was gathered on eyes eligible to switch but continued on aflibercept with the middle visit considered the "presumed switch." Outcome measures included visual acuity (VA) and central foveal thickness (CFT).

resultsA total of 142 eyes were analyzed with 71 in each of the switch and aflibercept groups. In the switch group, mean CFT increased from 165.7 µm at Sw to 184.7 µm at P1 (p = 0.009), 180.9 µm at P2 (p = 0.007), and 183.3 µm at P3 (p = 0.004). VA changed from logMAR 0.43 (20/54) at Sw to 0.49 (20/61) at P1 (p = 0.02), 0.54 (20/69) at P2 (p = 0.008), and 0.53 (20/68) at P3 (p = 0.04). In the aflibercept group, no significant change in CFT was found over the same period. VA changed from logMAR 0.56 (20/72) at the "presumed switch" to 0.58 (20/76) at P1 (p = 0.085), 0.62 (20/83) at P2 (p = 0.001), and 0.59 (20/77) at P3 (p = 0.14).

conclusionsnAMD eyes that were stable or improving on aflibercept but were switched to ranibizumab worsened, while those in a comparable group maintained on aflibercept remained fairly stable, suggesting a potential efficacy difference between the two drugs.

Indexed as

Macular DegenerationRanibizumabAngiogenesis InhibitorsCohort StudiesHumansNeovascularization, PathologicReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal VesselsRetrospective StudiesTreatment OutcomeafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAge-related macular degenerationRanibizumabSwitch

Identifiers

PMID35230472
OpenAlexW4214701813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.